Skip to main content

Table 2 Sensitivity and specificity of CSF and serum VILIP-1 for discrimination between AD and the other diagnostic groups except CJD

From: Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer’s and other neurodegenerative diseases

 

AD vs.

Calculated cut-offs

Sensitivity (95% CI) [%]

Specificity (95% CI) [%]

AUCs (95% CI)

Positive likelihood ratio

CSF VILIP-1

ND

>116

78 (67–86)

63 (50–73)

0.77 (0.70–0.85)

2

Con

>129

70 (59–79)

88 (79–94)

0.87 (0.82–0.93)

6

Serum VILIP-1

ND

>32

58 (46–68)

67 (55–77)

0.59 (0.50–0.69)

2

Con

>30

63 (52–73)

72 (61–81)

0.69 (0.60–0.77)

2

CSF t-tau

ND

>392

100 (95–100)

80 (68–88)

0.95 (0.92–0.99)

5

Con

>399

100 (95–100)

93 (85–97)

0.99 (0.98–100)

15

CSF p-tau 181

ND

>94

95 (87–98)

98 (92–99)

0.98 (0.97–1)

59

Con

>93

95 (87–98)

99 (92–100)

0.99 (0.98–1)

65

CSF Abeta 1-42

ND

<733

96 (89–99)

75 (63–84)

0.88 (0.83–0.94)

4

Con

<689

92 (83–96)

87 (77–93)

0.95 (0.92–0.98)

7

CSF VILIP-1/CSF Abeta 1-42

ND

>0.174

97 (91–100)

83 (72–90)

0.93 (0.89–0.97)

6

Con

>0.169

97 (91–100)

91 (82–95)

0.98 (0.97–1)

10

Serum VILIP-1/CSF Abeta 1-42

ND

>0.048

74 (63–83)

77 (65–85)

0.81 (0.74–0.89)

3

Con

>0.037

88 (78–93)

80 (70–88)

0.89 (0.84–0.95)

4

CSF t-tau/CSF Abeta 1-42

ND

>0.775

92 (83–96)

95 (87–99)

0.98 (0.96–1)

20

Con

>0.53

100 (95–100)

96 (89–99)

0.99 (0.99–1)

25

CSF p-tau 181/CSF Abeta 1-42

ND

>0.120

93 (85–97)

94 (85–98)

0.98 (0.96–1)

15

Con

>0.1

99 (93–100)

91 (82–96)

0.99 (0.98–1)

11

  1. Calculated cut-offs in picograms per milliliter for CSF and serum VILIP-1 as well as t-tau, p-tau, and Abeta 1-42. CI, confidence interval; Con, non-neurodegenerative control; ND, non-AD neurodegenerative diseases without CJD